Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation
{{output}}
Mutant RAS isoforms are the most common oncogenes affecting human cancers. After decades of effort in developing drugs targeting oncogenic RAS-driven cancers, we are still charting an unclear path. Despite recent developments exemplified by KRAS (G12C) inhibit... ...
